Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging safety profile in all NHL subtypes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback